Evidence map›Paper›PMID 40803852›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Clinical and Pathophysiological Characteristics of Patients in Whom Asthma Developed during Treatment with Immune Checkpoint Inhibitors: A Retrospective Single-center Study.

Ken Maeno, Tomoko Tajiri, Satoshi Fukuda, Tomohiro Onuki, Keima Ito, Yuta Mori, Kensuke Fukumitsu, Yoshihiro Kanemitsu, Takehiro Uemura, Hirotsugu Ohkubo and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ken MaenoDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan.
Tomoko TajiriDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan.
Satoshi FukudaDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan.
Tomohiro OnukiDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan.
Keima ItoDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan.
Yuta MoriDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan.
Kensuke FukumitsuDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan.
Yoshihiro KanemitsuDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan.
Takehiro UemuraDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan.
Hirotsugu OhkuboDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan.
Tetsuya OguriDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan.
Akio NiimiDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asthma develops as an immune-related adverse event; however, its clinical and pathophysiological characteristics remain unclear. We retrospectively reviewed five cases of asthma that developed during immune checkpoint inhibitor (ICI) treatment in patients with cancer. In all cases, a significant increase in blood eosinophil count was observed immediately before the onset of asthma symptoms, and serum allergen-specific immunoglobulin E antibodies were positive. ICI treatment could be continued safely, while temporarily suspended in two patients, under asthma treatment. The incidence of asthma was 0.97% (5/514). Early diagnosis and standard treatment enable good asthma control while continuing ICI therapy.

Indexed as

AsthmaImmune Checkpoint InhibitorsNeoplasmsAdultAgedAged, 80 and overFemaleHumansImmunoglobulin EMaleMiddle AgedRetrospective StudiesImmune Checkpoint InhibitorsImmunoglobulin Easthmaeosinophiliaimmune checkpoint inhibitorsimmune-related adverse events

Identifiers

PMID40803852
PMCPMC13019025

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.